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clinical symptoms, such as wheezing, shortness of 
breath, chest tightness, and cough. In late allergic 
response, bronchial infiltration of inflammatory 
cells is observed, which leads to tissue remodel‑
ing and irreversible respiratory obstruction.6,7
Omalizumab, the first antibody introduced to 
the market for a wide application in asthma ther‑
apy, binds free IgE in the circulation and prevents 
its attachment to the surface of inflammatory 
cells. The reduction of free IgE levels in serum 
results in a decrease in the levels of receptors for 
IgE on inflammatory cells, preventing them from 
responding to allergens.8,9 In clinical trials, omal‑
izumab was shown to reduce the rates of asthma 
exacerbation and hospitalizations, reduce daily in‑
haled and oral glucocorticoid doses, and improve 
the quality of life. It was also well tolerated, with 
an adverse event profile similar to that of place‑
bo.10,11 Omalizumab was approved for the treat‑
ment of severe allergic asthma by the Food and 
Drug Administration in the United States in 2003 
and by the European Union in 2005. Also in Po‑
land, since 2013, patients with severe allergic 
asthma who are aged 12 years or older and who 
have positive skin prick test results or in vitro re‑
activity to perennial aeroallergens, may be treated 
with this antibody within the national treatment 
program of the Polish National Health Fund.2,12 
The inclusion and exclusion criteria for this pro‑
gram have been determined based on Appendix 
B.44 of the Minister of Health Official Journal: 
“Treatment of severe IgE ‑dependent allergic asth‑
ma with omalizumab.”13 The most important cri‑
teria in this program are the use of an oral gluco‑
corticoid in the preceding 6 months and fulfill‑
ment of at least 3 of the following conditions: 1) 
significantly impaired quality of life due to asth‑
ma symptoms; 2) 3 or more severe exacerbations 
in the previous year, which required the use of or 
an increasing dose of systemic glucocorticoid; 3) 
hospitalization due to asthma exacerbation within 
the previous year; 4) a history of a life ‑threatening 
incident of an asthma attack; and 4) persistent 
To the Editor Asthma is one of the most com‑
mon noninfectious chronic obstructive diseases 
of the respiratory tract. It affects approximate‑
ly 5% to 7% of the population worldwide, includ‑
ing Poland.1 The basic objective in asthma treat‑
ment is to control disease symptoms by appropri‑
ate pharmacotherapy, as well as to reduce the risk 
of severe exacerbations.2 However, in approxi‑
mately 5% to 10% of patients, these targets are 
not achieved despite administration of standard 
medications at the highest therapeutic doses. In 
such cases, the condition is termed “severe asth‑
ma,” which is defined by the World Health Or‑
ganization as an uncontrolled disease associat‑
ed with the risk of frequent, severe exacerba‑
tions (or death) and/or adverse side effects of 
the treatment and/or impairment of pulmonary 
function.3 The term severe asthma is also used 
to describe patients who, within the preceding 
year, required a large dose of an inhaled gluco‑
corticoid together with an inhaled long ‑acting β2‑
‑agonist, or used oral glucocorticoid for at least 6 
months, but the disease remained uncontrolled 
despite treatment.4
Severe asthma (ie, asthma resistant to treat‑
ment) is problematic both for the patient (as it 
is associated with poor quality of life, adverse 
effects of medications, frequent and unexpect‑
ed exacerbations and hospitalizations) and for 
the health care system. To improve the therapy 
of severe asthma, attempts have been made to 
identify asthma phenotypes and develop an in‑
dividualized and phenotype‑directed treatment 
approach. The phenotypes include severe allergic 
asthma, which is challenging both for physicians 
and patients. In allergen ‑induced asthma, immu‑
noglobulin E (IgE) and T helper cell 2 ‑mediated 
eosinophilic inflammation play an important 
role.5 In early allergic reaction, exposure to al‑
lergens results in the release of proinflammato‑
ry mediators, which are responsible for contrac‑
tion of the airway smooth muscle and increased 
mucus production, leading to the development of 
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respiratory obstruction (forced expiratory volume 
in 1 second <60% of the predicted value or daily 
peak expiratory flow changes >30%).
Omalizumab is given in 1 or more subcutane‑
ous injections, once every 2 or 4 weeks (the dose 
is determined based on the body weight and IgE 
levels prior to therapy initiation).12
In our department, 40 patients so far have 
started omalizumab treatment. This makes our 
center one of the largest in Poland in terms of rou‑
tine omalizumab use. In a retrospective analysis of 
31 patients who continued treatment for at least 
24 months, 22 were women (71%), the median 
age at diagnosis was 21 years (range, 6–33 years), 
while the median age at the onset of omalizum‑
ab therapy was 45 years (range, 39–53 years). 
The most common allergens, with confirmed rela‑
tion to asthma symptoms, were house dust mites 
(n = 22; 71%), mold (n = 7; 23%) and cat dander (n 
= 12; 39%). The median IgE level was 203 IU/ml 
(range, 100–431 IU/ml). During treatment, we 
observed an improvement in the quality of life, 
a decrease in the number of exacerbations, and 
a reduction in oral glucocorticoid dose (TABLE 1). 
Despite the trend for better lung function and 
decrease in peripheral eosinophilia, differences 
were not significant.
In conclusion, therapy with omalizumab for 
severe asthma14 is available in daily practice as 
an add ‑on treatment also in Poland. Currently, 
more than 90% of our treated patients are re‑
cruited from the city of Kraków and its vicini‑
ty. We believe that there are many more eligible 
patients in smaller cities and rural areas of Po‑
land. With appropriate knowledge of the inclu‑
sion criteria, not only pulmonologists but also 
internists might refer patients to centers offer‑
ing omalizumab therapy.
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TABLE 1 Clinical and laboratory characteristics of patients with asthma at baseline and after 104 weeks of 
omalizumab therapy
Parameter Baseline 104 weeks of treatment P value
Inhaled corticosteroid dose, mg, recalculated 
to fluticasone
2000 (1000–2500) 2000 (1000–2500) 0.85
Oral corticosteroid dose, mg, recalculated to 
methylprednisolone
8 (4–16) 0 (0–8) 0.0002
Asthma Control Questionnaire, points 3.1 (2.8–3.5) 2 (1.1–3) 0.0003
Asthma Quality of Life Questionnaire, points 3.2 (2.8–3.87) 5.1 (4.5–6.3) <0.0001
Forced expiratory volume in 1 second, % of 
the predicted value
66 (55–83) 77 (71–84) 0.29
Exacerbations in the last year, n 4 (3–6) 0.5 (0–2) <0.0001
Blood eosinophilia, number/µl 240 (120–400) 160 (90–250) 0.12
Data are presented as median (range). A P value of less than 0.05 was considered significant.
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